{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Reddy MV"],"funding":["NCI NIH HHS"],"pagination":["6254-76"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4503467"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["54(18)"],"pubmed_abstract":["Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer. Accordingly, there is an increasing awareness of this novel nonenzymatic target for cancer therapeutics. We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells. The development of derivatized styrylbenzylsulfones followed logically from a tumor cell cytotoxicity screen performed in our laboratory that did not have an a priori target profile. Modifications of some of the precursor molecules led to lead optimization with regard to tumor cell cytotoxicity. In this report we describe the synthesis and structure-activity rel"],"journal":["Journal of medicinal chemistry"],"pubmed_title":["Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity."],"pmcid":["PMC4503467"],"funding_grant_id":["R01 CA109820","CA109820","R01 CA109820-06"],"pubmed_authors":["Reddy MV","Cosenza SC","Reddy EP","Pallela VR","Venkatapuram P","Mallireddigari MR","Robell KA","Akula B","Hoffman BS"],"additional_accession":[]},"is_claimable":false,"name":"Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity.","description":"Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer. Accordingly, there is an increasing awareness of this novel nonenzymatic target for cancer therapeutics. We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells. The development of derivatized styrylbenzylsulfones followed logically from a tumor cell cytotoxicity screen performed in our laboratory that did not have an a priori target profile. Modifications of some of the precursor molecules led to lead optimization with regard to tumor cell cytotoxicity. In this report we describe the synthesis and structure-activity rel","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Sep","modification":"2025-04-19T07:19:06.348Z","creation":"2019-03-27T01:55:10Z"},"accession":"S-EPMC4503467","cross_references":{"pubmed":["21812421"],"doi":["10.1021/jm200570p"]}}